Ascendis Pharma Presents New Data and Updated Results from&#

-  40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2...

Related Keywords

United States , Copenhagen , Køavn , Denmark , American , Chicago May , Stina Singel , Melinda Baker , Ascendis Pharma , Tim Lee , Head Of Clinical Development , Exchange Commission , Patti Bank , American Society Of Clinical Oncology , Believe Trial , American Society , Clinical Oncology , Executive Vice President , Clinical Development , Ascendi Annual Report ,